Skip to main content

Table 1 Clinical data of the 180 study patients

From: Comparing outcomes of single-port insufflation endoscopic breast-conserving surgery and conventional open approach for breast cancer

Variable

SIE-BCS

(N = 63)

C-BCS

(N = 117)

p value

Age (years)

  

0.961

 Mean

52.8 ± 8.7

54.0 ± 10.4

 Range

35.0–66.0

19.0–70.0

Premenopausal, n (%)

24 (38.1%)

41 (35.0%)

0.770

Neoadjuvant chemotherapy, n (%)

7 (11.1%)

10 (8.5%)

0.381

cTNM stage, n (%)

  

0.510

 I

32 (50.8%)

49 (41.9%)

 

 IIA

22 (34.9%)

47 (40.1%)

 

 IIB

9 (14.3%)

21 (18.0%)

 

PR, n (%)

  

0.061

 Positive

47 (74.6%)

71 (60.7%)

 

 Negative

16 (25.4%)

46 (39.3%)

 

ER, n (%)

  

0.619

 Positive

51 (80.9%)

91 (77.8%)

 

 Negative

12 (19.1%)

26 (22.2%)

 

HER2, n (%)

  

0.011

 Positive

5 (7.9%)

27 (23.1%)

 

 Negative

58 (92.1%)

90 (76.9%)

 

Tumor location, n (%)

  

0.285

 Lateral upper quadrant

42 (66.7%)

67 (57.3%)

 

 Lateral lower quadrant

2 (3.2%)

8 (6.8%)

 

 Medial upper quadrant

17 (26.9%)

31 (26.5%)

 

 Medial lower quadrant

2 (3.2%)

11 (9.4%)

 

SLNB or ALND, n (%)

  

0.452

 SLNB only

49 (77.8%)

85 (72.6%)

 

 SLNB and ALND

14 (22.2%)

32 (27.4%)

 

pT staging, n (%)

  

0.672

 pT1

45 (71.4%)

80 (73.8%)

 

 pT2

18 (28.6%)

37 (26.2%)

 

pN staging, n (%)

  

0.517

 pN0

46 (73.0%)

80 (68.4%)

 

 pN1

17 (27.0%)

37 (31.6%)

 

Degree of tumor differentiation, n (%)

  

0.930

 G1

6 (9.5%)

12 (10.3%)

 

 G2

52 (82.5%)

94 (80.3%)

 

 G3

5 (8.0%)

11 (9.4%)

 

Tumor type, n (%)

  

0.731

 Invasive ductal carcinoma

54 (85.7%)

102 (87.2%)

 

 Mucinous carcinoma

3 (4.8%)

3 (2.6%)

 

 Preinvasive carcinoma

6 (9.5%)

12 (10.2%)

 

Tumor size (cm)

  

0.440

 Mean

1.90 ± 0.7

1.95 ± 0.8

 Range

0.60–3.20

0.60–4.00

 
  1. HER2 status was estimated using immunohistochemistry or in situ hybridization. Tumors were considered HER2 positive if the average immunohistochemistry showed (+++). The HER2 gene/chromosome 17 ratio was 2, and the average HER2 gene copy number was 6. SIE-BCS single-port insufflation endoscopic breast-conserving surgery; C-BCS conventional breast-conserving surgery; cTNM clinical tumor, node, and metastasis; ER estrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor receptor type 2; SLNB sentinel lymph node biopsy; ALND axillary lymph node dissection; pT staging pathological tumor staging; pN staging pathological lymph node staging